Alternative Funding Mechanisms for Biologics
Advancing biologics through commercialization is a long process. Traditional funding routes such Initial public offerings (IPO) are less common, venture capital and private equity firms can be more selective, and the mergers & acquisition (M&A) option isn’t always available for pre-clinical and early-stage companies. Fortunately, traditional funding routes are not the only options for advancing … Read more